RESUMO
Treating ovarian cancer is a major challenge often hindered by late diagnosis, tumour recurrence and resistance to chemotherapeutic drugs. Recent findings from research studies of symptoms have for the first time provided a solid platform for establishing a symptoms awareness campaign. This gives hope to many that in the future women will benefit from prompt diagnosis, and improved five-year survival rates.
Assuntos
Detecção Precoce de Câncer/métodos , Programas de Rastreamento/métodos , Neoplasias Ovarianas/diagnóstico , Mulheres/educação , Diagnóstico Tardio , Erros de Diagnóstico , Detecção Precoce de Câncer/enfermagem , Feminino , Educação em Saúde , Humanos , Programas de Rastreamento/enfermagem , Anamnese , Estadiamento de Neoplasias , Enfermeiros Clínicos , Papel do Profissional de Enfermagem , Enfermagem Oncológica , Neoplasias Ovarianas/epidemiologia , Neoplasias Ovarianas/etiologia , Neoplasias Ovarianas/terapia , Medição de Risco , Fatores de Risco , Comportamento de Redução do Risco , Taxa de Sobrevida , Reino Unido/epidemiologiaAssuntos
Parto Obstétrico/enfermagem , Tocologia/métodos , Papel do Profissional de Enfermagem , Relações Enfermeiro-Paciente , Satisfação do Paciente , Feminino , Humanos , Pesquisa Metodológica em Enfermagem , Unidade Hospitalar de Ginecologia e Obstetrícia/organização & administração , Garantia da Qualidade dos Cuidados de Saúde , Saúde da MulherRESUMO
Survivin is a protein with proposed roles in cell division and apoptosis. Transcripts encoding splice variants of human survivin have been described and their expression correlated with cancer progression. As survivin forms homodimers in vitro, it has been suggested that these isoforms could interfere with wild type function by forming heterodimers. Here we show that survivin-2beta and survivin-deltaEx3 can interact with wild type survivin but have reduced affinity for the partner protein of survivin, borealin, and thus do not localize with the chromosomal passenger complex in vivo. Furthermore, we demonstrate that overexpression of survivin-2beta-green fluorescent protein (GFP) or survivin-deltaEx3-GFP does not impede cell cycle progression. We also report that wild type survivin, but not survivin-2beta-GFP or survivin-deltaEx3-GFP, can rescue cell proliferation inhibited by small interfering RNA-mediated survivin depletion. These data suggest that, despite their ability to interact with wild type survivin, neither of these isoforms acts as its competitor during mitosis nor has an essential function.